• Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update

    ソース: Nasdaq GlobeNewswire / 26 10 2022 02:00:00   America/New_York

    LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30, 2022 on Wednesday, November 9, 2022 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

    To participate, please dial one of the following numbers and ask to join the Verona Pharma call:

    • +1-866-652-5200 for callers in the United States
    • +1-412-317-6060 for international callers

    A live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for 90 days.

    For further information please contact:

    Verona Pharma plcUS Tel: +1-833-417-0262
    UK Tel: +44 (0)203 283 4200
    Victoria Stewart, Director of Investor Relations and CommunicationsIR@veronapharma.com
      
    Argot Partners
    (US Investor Enquiries)
    Tel: +1-212-600-1902
    verona@argotpartners.com
    Kimberly Minarovich / Carrie McKim 
      
    Optimum Strategic Communications
    (International Media and European Investor Enquiries)
    Tel: +44 (0)203 882 9621
    verona@optimumcomms.com
    Mary Clark / Rebecca Noonan / Zoe Bolt 
      

    About Verona Pharma

    Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ensifentrine met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function. ENHANCE-1 is expected to report around the end of 2022. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in the ENHANCE-2 trial. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.


    Primary Logo

シェアする